# Maryalice Stetler‐Stevenson

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/maryalice-stetler-stevenson/

## Facts

| Field | Value |
| --- | --- |
| Citations | 29,550 |
| Field | Chronic Lymphocytic Leukemia Research |
| h-index | 75 |
| i10-index | 198 |
| Last Known Institution | National Cancer Institute |
| OpenAlex ID | https://openalex.org/A5065696086 |
| ORCID iD | https://orcid.org/0000-0003-2591-0353 |
| Works | 380 |

## Researcher papers

- [T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial](https://scholariq.org/papers/t-cells-expressing-cd19-chimeric-antigen-receptors-for-acute-lymphoblastic/)
- [Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor](https://scholariq.org/papers/chemotherapy-refractory-diffuse-large-b-cell-lymphoma-and-indolent-b-cell/)
- [CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy](https://scholariq.org/papers/cd22-targeted-car-t-cells-induce-remission-in-b-all-that-is-naive-or-resistant/)
- [Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19](https://scholariq.org/papers/eradication-of-b-lineage-cells-and-regression-of-lymphoma-in-a-patient-treated/)
- [The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia](https://scholariq.org/papers/the-lymph-node-microenvironment-promotes-b-cell-receptor-signaling-nf-b/)
- [Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma](https://scholariq.org/papers/inhibition-of-b-cell-receptor-signaling-by-ibrutinib-in-primary-cns-lymphoma/)
- [CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial](https://scholariq.org/papers/cd4-cd8-t-cell-selection-affects-chimeric-antigen-receptor-car-t-cell-potency/)
- [Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL](https://scholariq.org/papers/long-term-follow-up-of-cd19-car-t-cell-therapy-in-children-and-young-adults-with/)
- [Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia](https://scholariq.org/papers/clonal-evolution-leading-to-ibrutinib-resistance-in-chronic-lymphocytic-leukemia/)
- [Both variant and IGHV4-34–expressing hairy cell leukemia lack the BRAF V600E mutation](https://scholariq.org/papers/both-variant-and-ighv4-34-expressing-hairy-cell-leukemia-lack-the-braf-v600e/)

## Researcher topics

- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Acute Lymphoblastic Leukemia research](https://scholariq.org/topics/acute-lymphoblastic-leukemia-research/)

## Researcher university

- [National Cancer Institute](https://scholariq.org/institutions/national-cancer-institute-3/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.